ORA busy training new investigators
This article was originally published in The Silver Sheet
FDA's Office of Regulatory Affairs (ORA) is training an influx of new investigators and adjusting to the retirement of some of its most experienced staffers. According to Michael Chappell, acting associate commissioner for regulatory affairs in ORA, the office has hired more than 700 new device, drug and other investigators, and 70 analysts since 2008. This means about 30 percent of ORA's investigators are new, Chappell said at a recent Food and Drug Law Institute meeting in Washington, D.C. "This creates some major training and mentoring challenges," he said. Nevertheless, Chappell reiterated the new administration's commitment to stronger enforcement at FDA. The agency is already issuing warning letters much faster following an inspection, he said. In the first half of fiscal year 2010, FDA issued 378 warning letters, while it issued only 473 during the entire fiscal year 2009, Chappell noted
You may also be interested in...
ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.